On May 19, 2004 Bristol Myers Squibb announced that it would take Serzone off the U.S. market. Serzone has long been associated with liver damage and liver failure. Bristol Myers Squibb had previously removed the drug from all major markets except the United States. The side effects of Serzone include jaundice, dark colored urine, loss of appetite, yellowing of the whites of the eyes, nausea, abdominal pain, and physical discomfort or uneasiness.

Serzone is a drug manufactured by Bristol-Myers Squibb Co. used to treat depression. Serzone was first introduced to the U.S. market with no warning of liver toxicity, although pre-clinical trials indicated the possibility of liver damage in some patients. The FDA subsequently required Squibb to include a warning on the label, which warns of "rare reports of liver necrosis and liver failure, in some cases leading to liver transplantation and/ or death." Six months later, the FDA required Squibb to remove the word "rare" from the warning statement, and finally to place a "Black Box" warning on the safety label. A Black Box warning label is the most serious warning issued by the Federal Food and Drug Administration. Less than a month later, Bristol-Myers Squibb advised health care providers that Serzone had been associated with cases of life-threatening liver failure.

If you or a loved one has taken Serzone, please submit the accompanying form. You may be entitled to collect monetary awards for your injury!